SG
HKPD

StoneX Group’s Cellyan Biotechnology HKPD Stock Holding History

StoneX Group’s Portfolio HKPD Stock Details HKPD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4K Sell
39,395
-3,889
-9% -$2.83K ﹤0.01% 827
2025
Q4 		$35.7K Buy
+43,284
New +$46.4K ﹤0.01% 947

Other funds holding HKPD

CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

StoneX Group's HKPD Position: Q1 2026 in Review

StoneX Group reduced its Cellyan Biotechnology (HKPD) stake by 9% in Q1 2026, selling an estimated $2.83K and leaving 39,395 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #827.

StoneX Group first reported a position in HKPD in Q4 2025 and has held it in 2 quarters since. The position peaked at $35.7K in Q4 2025. 4 funds tracked by Wall St. Rank hold HKPD as of Q1 2026.

  • StoneX Group held 39,395 shares of Cellyan Biotechnology worth $22.4K as of Q1 2026.
  • StoneX Group sold 3,889 Cellyan Biotechnology shares in Q1 2026, an estimated $2.83K.
  • Cellyan Biotechnology made up ﹤0.01% of StoneX Group's portfolio in Q1 2026, its #827 holding.
  • StoneX Group first reported a position in Cellyan Biotechnology in Q4 2025 and has held it in 2 quarters since.
  • StoneX Group's Cellyan Biotechnology position peaked at $35.7K in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Cellyan Biotechnology as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.